Crystal structure of pomalidomide Form I, C 13 H 11 N 3 O 4
Source abstract
Abstract
The crystal structure of pomalidomide Form I has been solved and refined using synchrotron X-ray powder diffraction data and optimized using density functional theory techniques. Pomalidomide Form I crystallizes in the space group P -1 (#2) with a = 7.04742(9), b = 7.89103(27), c = 11.3106(6) Å, α = 73.2499(13), β = 80.9198(9), γ = 88.5969(6)°, V = 594.618(8) Å 3 , and Z = 2. The crystal structure is characterized by the parallel stacking of planes parallel to the bc -plane. Hydrogen bonds link the molecules into double layers also parallel to the bc -plane. Each of the amine hydrogen atoms acts as a donor to a carbonyl group in an N–H⋯O hydrogen bond, but only two of the four carbonyl groups act as acceptors in such hydrogen bonds. Other carbonyl groups participate in C–H⋯O hydrogen bonds. The powder pattern has been submitted to ICDD® for inclusion in the Powder Diffraction File™ (PDF®).
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Pigment Synthesis and Properties · Crystal Structures and Properties
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (32)
Show source-provided references
1. 2020
2. 10.1107/S002188981101462210.1107/S0021889811014622 ↗
3. 10.1107/S002188981301311310.1107/S0021889813013113 ↗
4. 10.1017/S088571561800082910.1017/S0885715618000829 ↗
5. 10.1107/S010876819901508610.1107/S0108768199015086 ↗
6. Chen, R. S. , Muller, G. W. , Jaworsky, M. S. , Saindane, M. T. , and Cameron, L. M. (2005). “Polymorphic forms of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione,” International Patent Application WO 2005/023192 A2.
7. 10.1186/1758-2946-3-3310.1186/1758-2946-3-33 ↗
8. 10.1017/S088571561400051710.1017/S0885715614000517 ↗
9. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
10. Etudes sur la loi de bravais
11. Bravais · 1866
12. 10.1021/ar00172a00510.1021/ar00172a005 ↗
13. 10.1002/anie.19951555110.1002/anie.199515551 ↗
14. 10.1021/ci049780b10.1021/ci049780b ↗
15. 2013
16. 10.1063/1.46788210.1063/1.467882 ↗
17. 10.1093/nar/gky103310.1093/nar/gky1033 ↗
18. 10.1063/1.296926010.1063/1.2969260 ↗
19. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
20. Turner · 2017
21. 10.1017/S088571561900081210.1017/S0885715619000812 ↗
22. 10.1107/S205252061402290210.1107/S2052520614022902 ↗
23. Atwood, J. L. (2017). “Crystalline 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione dihydrate, compositions and methods of use thereof,” US Patent 10,093,647 B1.
24. 10.1107/S002188980201523610.1107/S0021889802015236 ↗
25. A new law of crystal morphology extending the law of Bravais
26. 10.1007/BF0054909610.1007/BF00549096 ↗
27. 10.1107/S002188981300353110.1107/S0021889813003531 ↗
28. 2020
29. Reddy, B. P. , Reddy, K. R. , Reddy, D. M. , Reddy, M. R. , and Krishna, B. V. (2014). “Process for pomalidomide,” International Patent Application WO 2014/170909 A2.
30. 10.1107/S090904950801843810.1107/S0909049508018438 ↗
31. 10.1002/qua.2465810.1002/qua.24658 ↗
32. Reddy, B. P. , Reddy, K. R. , Reddy, D. M. , Reddy, M. R. , and Krishna, B. V. (2017). “Process for pomalidomide,” US Patent Application 2017/0088537 A1.